← Back to patent-cliff list
Bepotastine Calcium Dihydrate
Tier C — Watch / tradeBepotastine Calcium Dihydrate
Hanmi Pharmaceutical Co., Ltd.
Originator
2010
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HRH1
Brand：Potastin, Potastin OD
Indications (approved)：Perennial allergic rhinitis
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bepotastine Calcium Dihydrate?
Approved indications include: Perennial allergic rhinitis.
When does the Bepotastine Calcium Dihydrate patent expire?
No public expiry year is available for Bepotastine Calcium Dihydrate yet; this page updates once verified.
How do I get a quote for Bepotastine Calcium Dihydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29